Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Three Formulations of NNC0471-0119 in Type 1 Diabetes
NCT05262595Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0471-0119 in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Novo Nordisk. Primary endpoint: AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected). Started Mar 2022; status: completed.
02
Drugs
NNC0471-0119
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05262595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262595.